<DOC>
	<DOCNO>NCT00048958</DOCNO>
	<brief_summary>Chromosomal analysis study genetic difference patient previously untreated AML , ALL , MDS MM may helpful diagnosis classification disease . It may also improve ability predict course disease selection therapy . Institutions must either Alliance-approved cytogeneticist agreement Alliance-approved main member cytogenetics laboratory enroll patient CALGB 8461 . The Alliance Approved Institutional Cytogeneticists list post Alliance Clinical Trials Oncology website .</brief_summary>
	<brief_title>Cytogenetic Studies Acute Leukemia Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Acute Disease</mesh_term>
	<criteria>1 . Patients adjuncts eligible Main Member Cytogenetics laboratory agree process sample adjunct . 2 . Within one month registration CALGB 8461 , register onto CALGB treatment study previously untreated AML , ALL , MDS , MM patient . 3 . Simultaneously registration CALGB 8461 , register patient within continental United States onto CALGB 9665 ( LTB ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>